Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Oxford Immunotec

Request full access

Proprietary T-cell based diagnostic tests for tuberculosis

Milton, United KingdomFounded 2001Biotech & Life Sciences

About Oxford Immunotec

Oxford Immunotec was a global diagnostics company that commercialized proprietary tests for immune-regulated conditions. Founded in 2002 as a spin-out from the University of Oxford by Dr. Peter Wrighton-Smith, the company focused on its T-SPOT technology platform. This platform measures the response of T-cells to specific antigens to diagnose various diseases.

The company's main product was the T-SPOT.TB test, an advanced blood test for diagnosing active and latent tuberculosis infection. This test offered higher sensitivity compared to traditional methods and was approved for sale in over 50 countries. The business model was based on selling these diagnostic test kits and offering laboratory services to process them. The company also expanded into tests for the transplantation market and tick-borne diseases.

After several rounds of venture capital funding, Oxford Immunotec went public on the NASDAQ in 2013. In January 2021, PerkinElmer announced its acquisition of Oxford Immunotec for approximately $591 million, which was finalized in March 2021. Subsequently, in May 2023, the life sciences and diagnostics businesses of PerkinElmer were rebranded as Revvity, and Oxford Immunotec's operations are now part of Revvity's portfolio.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2013

Oxford Immunotec in the Milton ecosystem

Live from Dealroom

The Oxford Immunotec office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Questor Capital
  • Prelude Trust
  • Dow

Series B and later10 investors entered at this stage

  • Wellington Partners
  • Clarus Ventures
  • NTEC
  • Molten Ventures
  • SPARK Ventures
  • New Leaf Venture Partners
  • Kaiser Permanente Ventures
  • Invesco
  • Imperial Innovations
  • Midcap Financial
Team profiled 26 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Oxford Immunotec on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.